Almirall to Collaborate with the Center for Genomic Regulation to Develop New Treatments

The Spanish multinational pharmaceutical company Almirall and the Center for Genomic Regulation (CRG) announced a collaboration agreement to identify new molecular signaling pathways and specific genetic markers of atopic dermatitis. This is a necessary condition for the development of new therapeutic approaches.

Under this agreement, Almirall will contribute its experience in modeling and fabric samples. The CRG will contribute its experience in the field of genomic research to identify possible markers that will allow more precise targeting of pharmacological solutions for atopic dermatitis. The two entities hope to expand the range of therapeutic options in this way.

It is not the first time that the Spanish pharmaceutical company and the research center collaborate. In 2023, an agreement was already executed to develop new preclinical models with which to identify possible treatments for skin cancer.

Read more about Almirall and the agreement with the Center for Genomic Regulation with our companion app. The Born2Invest mobile app keeps its readers up to date with the most important financial news of the day so you can stay on top of the market. Don’t waste your time scrolling the internet, let our team of seasoned writers do that for you.

Almirall has public financial support for the development of this initiative

The current project will last two years and will be financed by the Next Generation funds managed by the Center for Technological Development and Innovation (Cdti) and the Carlos III Health Institute.

Almirall is a Spanish pharmaceutical multinational specialized in medical dermatology founded in 1944. It is listed on the stock market and has around 1,800 employees around the world distributed in its own centers in 21 countries and subsidiaries in another 70 . At the time of writing these lines it has a capitalization of 1.77 billion euros.

The CRG is a biomedical research center created in 2000. More than 400 scientists work there dedicated to researching issues related to genes. This center is a member of the Barcelona Institute of Science and Technology (Bist).

__

(Featured image by Louis Reed via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us